Get the Stockscreener App
7.47
2.10%
-0.16
After Hours:
7.54
0.07
+0.94%
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth - TipRanks
(ORIC) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC's Latest Employee Stock Grants: Key Details on Compensation Package - StockTitan
Rhumbline Advisers Purchases 4,072 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World
ORIC Pharmaceuticals Reports Progress in Cancer Trials - TipRanks
ORIC Pharmaceuticals (ORIC) to Release Earnings on Monday - MarketBeat
Wedbush Expects Increased Earnings for ORIC Pharmaceuticals - MarketBeat
ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% After Analyst Upgrade - MarketBeat
(ORIC) Investment Analysis and Advice - Stock Traders Daily
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 - Defense World
ORIC Pharmaceuticals’ (ORIC) Buy Rating Reiterated at Guggenheim - Defense World
Wedbush Equities Analysts Lift Earnings Estimates for ORIC - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% on Analyst Upgrade - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 at JPMorgan Chase & Co. - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Buy" Rating from Guggenheim - MarketBeat
Oric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114 - TipRanks
ORIC® Pharmaceuticals Announces Focused Registrational - GlobeNewswire
Can ORIC Pharmaceuticals' Extended Cash Runway Fuel Success in Cancer Drug Development? - StockTitan
Wedbush Reduces Earnings Estimates for ORIC Pharmaceuticals - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Earnings Beat - MarketBeat
HC Wainwright Reaffirms Buy Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - Defense World
Wedbush Predicts Weaker Earnings for ORIC Pharmaceuticals - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
ORIC Pharmaceuticals Inc (ORIC) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
ORICOric Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up on Earnings Beat - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.6%Should You Sell? - MarketBeat
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Oric Pharmaceuticals, Inc. SEC 10-K Report - TradingView
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates - GlobeNewswire
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 6.4%Should You Sell? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpHere's What Happened - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 14.7%Here's What Happened - MarketBeat
ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright - MSN
Oric recent weakness a buying opportunity, says JPMorgan - MSN
ORIC’s price-to-book ratio: An indicator of the company’s performance - US Post News
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):